Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Elan provides update on safety of Tysabri

Elan provides update on safety of Tysabri

12th October 2007

Elan and Biogen Idec are set to announce new data on the global utilisation and safety of Tysabri (natalizumab) at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic this week.

The data presented will show that 17,000 patients are now receiving clinical therapy worldwide and that the safety data continues to support a favourable benefit-risk profile for Tysabri.

Elan will announce to the congress that there have been no new confirmed cases of progressive multifocal leukoencephalopathy (PML) for Tysabri users.

“Continued patient experience and ongoing clinical research will further differentiate Tysabri as a valuable treatment option for MS patients around the world,” said Gordon Francis senior vice president of global clinical development, Elan.

He went on to describe how Tysabri was currently approved in more than 20 countries and that Elan hoped to offer the therapeutic alternative to more patients in the future.

In the US 10,500 patients are on Tysabri commercially while in the EU it is around half that figure at 5,500 patients.

Last month, Elan announced the appointment of two new members of its board of directors, with the selection of Jonas Frick and Giles Kerr welcomed.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.